Nurix Therapeutics vs Ultragenyx Pharmaceutical
NRIX and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NRIX and RARE compare
Nurix Therapeutics and Ultragenyx Pharmaceutical are about the same size, with market caps of $1.7B and $1.6B.
Nurix Therapeutics grew revenue faster over the last twelve months (739% versus 15.8% for Ultragenyx Pharmaceutical).
Nurix Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.0% compared with −71.8% at Ultragenyx Pharmaceutical.
Nurix Therapeutics scores higher on the StockData Score (15 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NRIX | RARE |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $1.6B |
| Share price | $15.48 | $16.08 |
| Change, 1 year | 27.2% | −52.0% |
| Change, 5 years | −50.6% | −79.7% |
| Beta (5Y) | 1.46 | 1.07 |
| Employees | 317 | 1,371 |
| StockData Score | ||
| Total score | 15 (better) | 9 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 6.7× | – |
| P/S | 2.4× | 2.2× (better) |
| P/B | 1.7× | – |
| EV/EBITDA | 2.0× | – |
| P/FCF | 4.6× | – |
| FCF yield | 21.9% (better) | −27.9% |
| Fair value | $57.66 | – |
| Margin of safety | 73.2% | – |
| Growth | ||
| Revenue growth (TTM) | 739% (better) | 15.8% |
| Revenue growth, 5Y average | 36.3% (better) | 19.9% |
| Profitability | ||
| Operating margin | 41.3% (better) | −64.0% |
| Net margin | 42.0% (better) | −71.8% |
| FCF margin | 52.7% (better) | −60.5% |
| Return on equity | 44.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 8.44 (better) | 1.40 |
| Altman Z-score | 6.10 (better) | −5.73 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −1.1% | – |
| Shareholder yield | −1.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 107% | 108% |
| Held by insiders | 3.2% | 4.0% |
| Insider net buying, 12 months | −$5.2M | −$3.8M (better) |
| Short interest, % of float | 17.9% | 25.0% |
Go deeper
- NRIX stock overview
- NRIX income statement
- NRIX valuation and score
- RARE stock overview
- RARE income statement
- RARE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.